Compare Aurora Cannabis Inc (ACB) vs Innodata Inc (INOD) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

Innodata (INOD) trades at $73.12, up 6.16% today but down 33% over the past month after a strong AI-driven rally earlier this year. The stock shows bearish technical signals with support at $69 and resistance at $76. Fundamentally, the company reported strong Q1 2026 earnings with EPS of $0.42 beating expectations of $0.13, driven by 47% margins and AI data services growth. Revenue reached $90.1M in Q1 2026 (Zacks Investment Research, 2026-06-03).

Outlook remains positive with 60% analyst buy ratings and a $130 consensus price target, but risks include high valuation (P/E 65.29), insider selling, and dependence on AI sector momentum. The recent CFO appointment (Accesswire, 2026-06-17) supports growth execution, yet volatility near multi-month highs requires caution.